BiotechTube

AG-013736 (AXITINIB)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenoid Cystic Carcinoma

Conditions

Adenoid Cystic Carcinoma

Trial Timeline

Mar 1, 2012 → Aug 1, 2016

NCT ID
NCT01558661

About AG-013736 (AXITINIB)

AG-013736 (AXITINIB) is a phase 2 stage product being developed by Pfizer for Adenoid Cystic Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01558661. Target conditions include Adenoid Cystic Carcinoma.

What happened to similar drugs?

1 of 2 similar drugs in Adenoid Cystic Carcinoma were approved

Approved (1) Terminated (0) Active (1)
🔄Mometasone Furoate nasal spray + PlaceboOrganonPhase 3
✅mometasone furoate nasal sprayOrganonApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT01558661Phase 2Completed
NCT00919204Phase 1Completed
NCT00282048Phase 2Completed
NCT00071006Phase 2Completed

Competing Products

11 competing products in Adenoid Cystic Carcinoma

See all competitors
ProductCompanyStageHype Score
Enfortumab VedotinAstellas PharmaPhase 2
42
LenvatinibEisaiPhase 2
39
Lenvatinib + PembrolizumabEisaiPhase 2
39
P-SamAstraZenecaPhase 2
42
CetuximabMerckPhase 1/2
28
PembrolizumabMerckPhase 2
35
DovitinibNovartisPhase 2
35
Dovitinib (TKI258)NovartisPhase 2
35
RegorafenibBayerPhase 2
32
Mometasone Furoate nasal spray + PlaceboOrganonPhase 3
34
mometasone furoate nasal sprayOrganonApproved
37